BCL2 and acute myeloid leukemia: CRISPR/Cas9 screening platform have been used to identify genetic vulnerabilities in acute myeloid leukemia (AML) cells, including several established (such as DOT1L, BCL2, and MEN1) and novel (such as KAT2A) therapeutic targets for AML [88].